RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human primates following a single administration RNA Gene Writing™ platform generates tumor-clearing CAR T cells by all-RNA delivery RNA Gene Writers™ demonstrate programmable writing to facilitate targeted DNA integration and ability to make small and large changes at the same time in human cells DNA Gene Writing™ platform promotes sustained and high le

Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability eFFECTOR to focus on front-line PD-L1 ≥ 50% cohort of KICKSTART trial with tomivosertib in non-small cell lung cancer Management to present results and provide full pipeline update in investor call on January 5, 2023 at 4:30 p.m. ET SOLANA BEACH, Calif